Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF hamster model at the Keystone conference on type 2 Diabetes therapeutics, May 1-4 in Palm Springs, CA, USA

Physiogenex and its subsidiary company Cardiomedex will be presenting a new diabetic NASH HFpEF hamster model at the Keystone Symposia on type 2 diabetes therapeutics in Palm Springs, CA, USA May 1-4, 2023.

This unique preclinical model will be presented during the May 2ndposter session (poster #1005) from 7:30pmby Dr. François Briand, Director of Research and Business Development at Physiogenex, and Dr. Rana Assaly, Director of Scientific and Business Development at Cardiomedex.

Unlike mouse and rat, the diabetic NASH HFpEF hamster has a human-like lipoprotein/bile acids profile, shows evident hepatocellular ballooning and portal/bridging (stage 2-3) fibrosis, and develops alteration in kidney function and severe heart failure with preserved ejection fraction (HFpEF). This preclinical model represents a unique opportunity to evaluate the cardiometabolic benefits of drugs targeting type 2 diabetes and/or its complications.

Reach out to François Briand or Rana Assaly during the Keystone conference to learn how Physiogenex and Cardiomedex animal models and CRO services will drive your preclinical drug development to success.

Otherwise, contact us online to set-up an appointment with Dr. Briand or Dr.Assaly and/or discuss your drug development projects with us: